NCT01077154 2021-09-28
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Amgen
Phase 3 Terminated
Amgen
M.D. Anderson Cancer Center
Jules Bordet Institute
Northwestern University